Vigran, I. Myron
January 1964
Angiology;Jan1964, Vol. 15 Issue 1, p1
Academic Journal
A review has been presented of some of the more classical and recent findings in regard to results of anticoagulant therapy in acute myocardial infarction, the long-term prophylactic treatment of coronary artery disease, the use of anticoagulant therapy in cerebral vascular disease, as well as in postoperative thromboembolism. The most desirable procedures to be used for the control of oral anticoagulant therapy have been discussed as well as an evaluation as to which type of anticoagulant to use, i.e., heparin versus the oral anticoagulants. From this appraisal it appears that attention should be focused upon the evidence that anticoagulants effect morbidity more than they do mortality in most of the above mentioned conditions, as well as the fact that the role of heparin in anticoagulant therapy should be further evaluated on a clinical basis.


Related Articles

  • Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. Suzuki, Shunji; Sakamoto, Susumu; Okada, Takeaki; Matsuo, Miyako; Saitoh, Atsushi; Matsuo, Takefumi // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p341 

    A patient with systemic lupus erythematosus and anti-cardiolipin antibodies and antibodies to platelet factor 4/heparin complexes suffered an acute myocardial infarction caused by delayed heparin-induced thrombocytopenia after heparin administration given to treat pulmonary hypertension....

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...

  • Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction. Carter, Natalie J.; McCormack, Paul L.; Plosker, Greg L. // BioDrugs;2008, Vol. 22 Issue 5, p343 

    Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention. It binds to and...

  • Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI. Berger, Peter B. // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p11 

    This article presents a study related to effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction (MI) presenting with ST-segment elevation. Several patients were presented with suspected acute MI and ST-segment...

  • Traditional versus modern anticoagulant strategies: Summary of the literature. Nutescu, Edith; Racine, Eric // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS7 

    Traditional and modern anticoagulant therapies for the management, prophylaxis, and treatment of venous thromboembolism (VTE) and acute coronary syndrome (ACS) and key findings of primary studies are summarized, Significant advances have been made during the past decade in the prevention and...

  • Treatment Options in Acute Coronary Syndromes: Focus on Fondaparinux Sodium. Reindl, Iris; Schlitt, Axel // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p869 

    Anticoagulants are the mainstay for treating thromboembolism and acute coronary syndromes (ACS). In comparison to heparin newer agents such as bivalirudin and fondaparinux have improved the outcome of ACS in patients managed by using an invasive or conservative strategy, respectively. Using...

  • The Effect of Low Molecular Weight Heparin (Fragmin) on Myocardial Neutrophil Accumulation and Infarct Size in a Rat Model of Myocardial Infarction. Hasdai, David; Varda-Bloom, Nira; Blumberg, Nehemia; Ohad, Dan; Kornowski, Ran; Battler, Alexander // Angiology;May1996, Vol. 47 Issue 5, p491 

    Background: Heparin molecules possess immunomodulating properties, which are thought to complement their established antithrombotic activity. The purpose of this study was to evaluate whether the antiinflammatory properties of low molecular weight heparin (LMWH) can attenuate polymorphonuclear...

  • Prothrombin complex concentrate facilitates emergency spinal surgery in anticoagulated patients. Beynon, Christopher; Potzy, Anna; Unterberg, Andreas; Sakowitz, Oliver // Acta Neurochirurgica;Apr2014, Vol. 156 Issue 4, p741 

    Background: Oral anticoagulants are commonly used in the ageing population and therefore, spine surgeons are increasingly confronted with anticoagulated patients requiring surgical therapy. 'Bridging therapies' with heparins are established in elective settings, but the time frame for...

  • PRIMARY ANGIOPLASTY OR T-PA FOR THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION? Bailey, Gene; Flynn, Cheryl A. // Journal of Family Practice;Aug1999, Vol. 48 Issue 8, p577 

    The article presents information on a study that compared the efficacy of primary angioplasty and tissue-type plasminogen activator (t-PA) in managing acute myocardial infarction. A total of 395 patients were enrolled in the study between June 1990 and April 1992. Patients of any age presented...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics